BRPI0809996A2 - Compostos - Google Patents

Compostos

Info

Publication number
BRPI0809996A2
BRPI0809996A2 BRPI0809996-0A2A BRPI0809996A BRPI0809996A2 BR PI0809996 A2 BRPI0809996 A2 BR PI0809996A2 BR PI0809996 A BRPI0809996 A BR PI0809996A BR PI0809996 A2 BRPI0809996 A2 BR PI0809996A2
Authority
BR
Brazil
Prior art keywords
compounds
Prior art date
Application number
BRPI0809996-0A2A
Other languages
English (en)
Inventor
Peter William Sheldrake
Butrus Atrash
Simon Green
Edward Mcdonald
Sheelagh Frame
Original Assignee
Cyclacel Ltd
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd, Cancer Rec Tech Ltd filed Critical Cyclacel Ltd
Publication of BRPI0809996A2 publication Critical patent/BRPI0809996A2/pt
Publication of BRPI0809996B1 publication Critical patent/BRPI0809996B1/pt
Publication of BRPI0809996B8 publication Critical patent/BRPI0809996B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
BRPI0809996A 2007-04-04 2008-04-02 compostos, seus usos para tratar um distúrbio proliferativo, viral, neurodegenerativo, do snc, diabetes, alopecia e um acidente vascular cerebral, e composições farmacêuticas BRPI0809996B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92189707P 2007-04-04 2007-04-04
GBGB0706632.7A GB0706632D0 (en) 2007-04-04 2007-04-04 New purine derivatives
PCT/GB2008/001173 WO2008122767A2 (en) 2007-04-04 2008-04-02 2, 6, 9-substituted purine derivatives having anti proliferative properties

Publications (3)

Publication Number Publication Date
BRPI0809996A2 true BRPI0809996A2 (pt) 2014-10-14
BRPI0809996B1 BRPI0809996B1 (pt) 2019-09-03
BRPI0809996B8 BRPI0809996B8 (pt) 2021-05-25

Family

ID=38090893

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809996A BRPI0809996B8 (pt) 2007-04-04 2008-04-02 compostos, seus usos para tratar um distúrbio proliferativo, viral, neurodegenerativo, do snc, diabetes, alopecia e um acidente vascular cerebral, e composições farmacêuticas

Country Status (13)

Country Link
US (1) US8592581B2 (pt)
EP (1) EP2139893B1 (pt)
JP (1) JP5466145B2 (pt)
CN (1) CN101679434B (pt)
AU (1) AU2008235361B2 (pt)
BR (1) BRPI0809996B8 (pt)
CA (1) CA2681529C (pt)
ES (1) ES2427845T3 (pt)
GB (1) GB0706632D0 (pt)
MX (1) MX2009010660A (pt)
PL (1) PL2139893T3 (pt)
RU (1) RU2461559C2 (pt)
WO (1) WO2008122767A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0903346D0 (en) 2009-02-27 2009-04-08 Cambridge Advanced Tech Transgenic Plants
GB201001075D0 (en) * 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms
DE102011111400A1 (de) * 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
US9579198B2 (en) 2012-03-01 2017-02-28 Twelve, Inc. Hydraulic delivery systems for prosthetic heart valve devices and associated methods
EP4115882A1 (en) 2015-01-16 2023-01-11 The General Hospital Corporation Compounds for improving mrna splicing
WO2017146253A1 (ja) 2016-02-26 2017-08-31 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
KR102524773B1 (ko) * 2017-01-26 2023-04-21 싸이클라셀 리미티드 퓨린 유도체의 제조 방법
EP3388432A1 (en) 2017-04-10 2018-10-17 Commissariat à l'Energie Atomique et aux Energies Alternatives Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders
IL282737B2 (en) 2018-11-01 2025-05-01 Syros Pharmaceuticals Inc Cyclin-dependent kinase 7 (CDK7) inhibitors
RU2754441C2 (ru) * 2019-12-30 2021-09-02 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
GB202000901D0 (en) 2020-01-22 2020-03-04 Cyclacel Ltd Process
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
WO2024105159A1 (en) * 2022-11-16 2024-05-23 University Of Zurich Ligands of the m6a-rna readers
TW202440578A (zh) 2022-12-16 2024-10-16 瑞典商阿斯特捷利康公司 ２，６，９－三取代嘌呤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
DE60023268T2 (de) * 1999-02-01 2006-06-01 CV Therapeutics, Inc., Palo Alto INHIBITEURS PURIQUES DE KINASE 2 DEPENDANTE DES CYCLINES et IkB-alpha
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
JP4381804B2 (ja) * 2001-06-27 2009-12-09 サイクラセル リミテッド ２，６，９−置換プリン誘導体及び増殖性疾患の治療におけるその使用
US6812232B2 (en) * 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US20030229105A1 (en) * 2002-05-21 2003-12-11 Cyclacel Limited Treatment of autoimmune disorders
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
EP1590341B1 (en) * 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
ES2403558T3 (es) * 2004-08-27 2013-05-20 Cyclacel Limited Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias
GB0706633D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd Combination

Also Published As

Publication number Publication date
RU2009140753A (ru) 2011-05-10
MX2009010660A (es) 2010-02-17
AU2008235361A1 (en) 2008-10-16
ES2427845T3 (es) 2013-11-04
BRPI0809996B8 (pt) 2021-05-25
BRPI0809996B1 (pt) 2019-09-03
RU2461559C2 (ru) 2012-09-20
US20100093769A1 (en) 2010-04-15
US8592581B2 (en) 2013-11-26
WO2008122767A3 (en) 2008-12-31
WO2008122767A2 (en) 2008-10-16
HK1139939A1 (en) 2010-09-30
EP2139893A2 (en) 2010-01-06
PL2139893T3 (pl) 2013-11-29
AU2008235361B2 (en) 2013-02-14
JP5466145B2 (ja) 2014-04-09
GB0706632D0 (en) 2007-05-16
EP2139893B1 (en) 2013-06-19
CN101679434B (zh) 2013-09-25
CA2681529A1 (en) 2008-10-16
JP2010523534A (ja) 2010-07-15
CA2681529C (en) 2015-06-30
CN101679434A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
BRPI0813500A2 (pt) Compostos antivirais
BRPI0821086A2 (pt) Compostos inseticidas
DK2185567T3 (da) Substituerede bicyclolactam-forbindelser
BRPI0815042A2 (pt) Compostos de pirazol
EP2170350A4 (en) SUBSTITUTED IMIDAZOHETEROCYCLES
ATE542825T1 (de) Substituierte piperidino-dihydrothienopyrimidine
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt) compostos
DK2242759T3 (da) Forbindelser
ATE501136T1 (de) Imidazopyridinone
BRPI0811264A2 (pt) Compostos
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
DK2323972T3 (da) C7-fluor-substituerede tetracylinforbindelser
BRPI0809996A2 (pt) Compostos
BRPI0814424A2 (pt) Compostos heterociclila
BRPI0811451A2 (pt) Exopolissacarídeo
DK2297162T3 (da) Forbindelser
BRPI0812840A2 (pt) 2-imidazolinas
AT505058A3 (de) Türschliesssystem
BRPI0916432A2 (pt) compostos
BRPI0815181A2 (pt) Compostos
DK2206698T3 (da) Ethynylindolforbindelser
BRPI0814613A2 (pt) Compostos
PL3825306T3 (pl) Związki morfinanu
BRPI0922152A2 (pt) Compostos

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: CANCER RESEARCH TECHNOLOGY LTD (GB) , CYCLACEL LIM

B25G Requested change of headquarter approved

Owner name: CANCER RESEARCH TECHNOLOGY LTD (GB) , CYCLACEL LIM

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF